STAAR Surgical to Conduct Earnings Conference Call and Webcast for the Second Quarter of 2025 on August 6, 2025
STAAR Surgical Faces Near-Term Challenges Amid Acquisition, but Long-Term Prospects Remain Bright
In a financial report released on August 6, 2025, STAAR Surgical, a leading global provider of implantable phakic intraocular lenses, reported mixed results for its Q2 2025 performance.
Based in Lake Forest, California, STAAR operates research, development, manufacturing, and packaging facilities in California and Switzerland. The company is best known for its EVO ICL™ product line, which provides visual freedom through a quick, minimally invasive procedure. Over the years, STAAR has sold more than 3 million ICLs in over 75 countries.
The Q2 2025 financial results showed a sharp net loss of $16.8 million, a 327.8% decline from the net income of $7.4 million in the prior year quarter. This decline was primarily due to reduced revenue and costs associated with restructuring amid the acquisition process.
Revenue dropped 55.2% year-over-year to $44.3 million, mainly because of inventory reduction and minimal purchases by distributors in China. However, regions outside China grew by about 10% year-over-year, showing geographic sales resilience.
Despite the revenue drop, the Q2 revenue and EPS figures exceeded analyst expectations. The GAAP revenue beat consensus by 9.4%, and the EPS loss was narrower than expected. However, the company withdrew its full-year 2025 financial guidance citing ongoing risks related to China market uncertainty and tariff issues.
The CEO emphasized cost-cutting and restructuring efforts to improve profitability over time, highlighting progress in narrowing losses sequentially from Q1 to Q2 2025.
The pending acquisition by Alcon, a leading global eye care company, at $1.5 billion ($28/share cash offer), represents a significant premium. This acquisition is expected to expand Alcon’s myopia treatment portfolio through STAAR’s EVO ICL technology, suggesting strategic growth potential beyond the current earnings weakness.
The live webcast for discussing the 2Q 2025 financial results will take place at 4:30 p.m. ET on Wednesday, August 6, 2025. The webcast link can be accessed at https://registrations.events/direct/IDX8578398. A replay of the webcast will be available on the "Investors" section of the STAAR website at https://investors.staar.com/.
For investor relations in the United States, contact Niko Liu, CFA at 626-303-7902 ext 3023 or +852-6092-5076 in Hong Kong, or email him at [email protected]. For general inquiries, contact Business Wire at [email protected].
STAAR Surgical has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs) since 1982. The company's ICLs are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens.
Despite the near-term financial challenges, the strategic acquisition by Alcon provides a basis for long-term optimism, as it aims to leverage STAAR’s technology to enhance its product offerings. The withdrawal of the FY 2025 guidance and continuation of operational risks underline ongoing uncertainty in the immediate future.
[1] Business Wire Press Release, STAAR Surgical Reports Second Quarter 2025 Financial Results, August 6, 2025. [2] STAAR Surgical Company website, About Us, accessed August 6, 2025. [3] Yahoo Finance, STAAR Surgical Co (STAA) Q2 2025 Earnings Call Transcript, August 6, 2025. [4] MarketWatch, STAAR Surgical Co (STAA) Q2 2025 Earnings Release, August 6, 2025. [5] Seeking Alpha, STAAR Surgical Co (STAA) Q2 2025 Earnings Call Transcript, August 6, 2025.
Cloud news suggests the ongoing uncertainty in STAAR Surgical's immediate financial future due to risks related to the China market and tariff issues. In the long term, however, the finance and investing community keeps a positive outlook on STAAR Surgical, with the strategic acquisition by Alcon aiming to leverage STAAR's technology to enhance its product offerings, suggesting potential growth in the business sector.
